Veidekke's Danish subsidiary Hoffmann has been awarded a contract to build a new national research and treatment centre for particle therapy in Aarhus in Jutland. This is a turnkey contract valued at DKK 280 million, excluding VAT.
The Danish Centre for Particle Therapy (DCPT) will be the only of its kind in Denmark, and the centre will be one of the world's leading centres for research and the treatment of cancer by particle-based radiation therapy. The new centre will have 9,500 m2 of floor space, and it will be built in connection with the cancer ward at Aarhus University Hospital.
The actual building will be divided into a clinical section with CT and MRI scanners and treatment rooms, and a bunker section that will house a proton accelerator and three linear accelerators. To prevent radiation spreading to the surroundings, concrete walls up to four metres thick will be cast with a very advanced solution for ventilation, cooling and waste water collection.
Construction will start in February, and the building will be ready to receive its first patient in September 2018.
For press photos, see www.flickr.com/photos/veidekke, for more information, contact:
CEO Torben Bjørk Nielsen of Hoffmann, tel. +45 43 29 93 00, mobile +45 60 12 93 00, tbn@hoffmann.dk
Communications Manager Helge Dieset of Veidekke, tel. +47 90 55 33 22, helge.dieset@veidekke.no
Subscribe to notices from Veidekke
Veidekke is one of Scandinavia's largest construction and property development companies. The company undertakes all types of building and construction contracts, maintains roads and produces asphalt and aggregates. The company is characterised by involvement and local knowledge. Revenue is NOK 24 billion (2014), and half of the 6,400 employees own shares in the company. Veidekke is listed on the Oslo Stock Exchange and has always posted a profit since it was founded in 1936.
| Title | File type |
| Illustration DCPT |